David A. Wetter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David A. Wetter has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Lisa A. Drage
Department of Dermatology, Mayo Clinic, Rochester, Minnesota
5 shared publicationsMichael J. Camilleri
Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota
5 shared publicationsM.D.P. Davis
Department of Dermatology Mayo Clinic Rochester Minnesota USA
3 shared publicationsMark D.P. Davis
Department of Dermatology, Mayo Clinic, Rochester, Minnesota
3 shared publicationsMark R. Pittelkow
Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA
3 shared publications- Michael J. Camilleri
Department of Dermatology, Mayo Clinic, Rochester, MN
3 shared publications
Latest Publications
- 22 September 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (3) , 520-530
Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa
Background: Perianal draining tunnels in hidradenitis suppurativa (HS) and perianal fistulizing inflammatory bowel disease (IBD) present diagnostic and management dilemmas.Methods: We conducted a retrospective chart review of patients with perianal disease evaluated at Mayo Clinic from January 1, 1998, through July 31, 2021. Patients' demographic and clinical data were extracted, and 28 clinical features were collected. After experimenting with several machine learning techniques, random forests were used to select the 15 most important clinical features to construct the diagnostic prediction model to distinguish perianal HS from fistulizing perianal IBD.Results: A total of 263 patients were included (98 with HS, 100 with IBD, and 65 with both IBD and HS). Patients with HS had a higher mean body mass index, a higher smoking rate, and more commonly showed cutaneous manifestations of tunnels and comedones, while fistulas, abscesses, induration, anal tags, ulcers, and anal fissures were more common in patients with IBD. In addition to having lesions in the perianal area, patients with IBD often had lesions in the buttocks and perineum, while those with HS had additional lesions in the axillae and groin. Among the statistically significant features, the 15 most important were identified by random forest: fistula, tunnel, digestive symptom, knife‐cut ulcer, perineum, body mass index, age, axilla, abscess, tags, smoking, groin, genital cutaneous edema, erythema, and bilateral/unilateral.Conclusions: The results of this study may help differentiate perianal lesions, especially perineal HS and fistulizing perineal IBD, and provide promise for a better therapeutic outcome.
- 22 September 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (3) , 520-530
Differentiating clinical characteristics of perianal inflammatory bowel disease from perianal hidradenitis suppurativa
Background: Perianal draining tunnels in hidradenitis suppurativa (HS) and perianal fistulizing inflammatory bowel disease (IBD) present diagnostic and management dilemmas.Methods: We conducted a retrospective chart review of patients with perianal disease evaluated at Mayo Clinic from January 1, 1998, through July 31, 2021. Patients' demographic and clinical data were extracted, and 28 clinical features were collected. After experimenting with several machine learning techniques, random forests were used to select the 15 most important clinical features to construct the diagnostic prediction model to distinguish perianal HS from fistulizing perianal IBD.Results: A total of 263 patients were included (98 with HS, 100 with IBD, and 65 with both IBD and HS). Patients with HS had a higher mean body mass index, a higher smoking rate, and more commonly showed cutaneous manifestations of tunnels and comedones, while fistulas, abscesses, induration, anal tags, ulcers, and anal fissures were more common in patients with IBD. In addition to having lesions in the perianal area, patients with IBD often had lesions in the buttocks and perineum, while those with HS had additional lesions in the axillae and groin. Among the statistically significant features, the 15 most important were identified by random forest: fistula, tunnel, digestive symptom, knife‐cut ulcer, perineum, body mass index, age, axilla, abscess, tags, smoking, groin, genital cutaneous edema, erythema, and bilateral/unilateral.Conclusions: The results of this study may help differentiate perianal lesions, especially perineal HS and fistulizing perineal IBD, and provide promise for a better therapeutic outcome.
- 26 May 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (12) , 2443-2450
Reactive granulomatous dermatitis as a clinically relevant and unifying term: a retrospective review of clinical features, associated systemic diseases, histopathology and treatment for a series of 65 patients at Mayo Clinic
Background: Reactive granulomatous dermatitis (RGD) is an umbrella term used to describe interstitial granulomatous dermatitis (IGD), palisaded neutrophilic and granulomatous dermatitis (PNGD), and interstitial granulomatous drug eruption (IGDR).Objective: The aim of this study was to describe systemic associations of RGD, explore possible associations between histopathologic findings and systemic RGD associations and determine clinical relevance of RGD subtypes.Methods: We retrospectively studied clinical and histopathologic characteristics of patients with RGD from 1990 through 2020.Results: Of 65 patients with RGD (41 women, 24 men; median age at diagnosis, 62 years), 37 had IGD, 26 had PNGD, and 2 had IGDR. Fifty patients (76.9%) had an associated systemic condition; rheumatologic conditions were identified for 34 (52.3%) patients. The associated systemic condition occurred before RGD in approximately 75% of patients. Statistical analyses did not show significant associations between specific subtypes of RGD and systemic diseases or treatment response, and specific histopathologic findings were not predictive of an associated systemic disease.Conclusions: Although most patients with RGD had an associated systemic condition, subtypes of RGD did not correlate with systemic associations, lending support to the use of the umbrella term RGD.
- 26 May 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (12) , 2443-2450
Reactive granulomatous dermatitis as a clinically relevant and unifying term: a retrospective review of clinical features, associated systemic diseases, histopathology and treatment for a series of 65 patients at Mayo Clinic
Background: Reactive granulomatous dermatitis (RGD) is an umbrella term used to describe interstitial granulomatous dermatitis (IGD), palisaded neutrophilic and granulomatous dermatitis (PNGD), and interstitial granulomatous drug eruption (IGDR).Objective: The aim of this study was to describe systemic associations of RGD, explore possible associations between histopathologic findings and systemic RGD associations and determine clinical relevance of RGD subtypes.Methods: We retrospectively studied clinical and histopathologic characteristics of patients with RGD from 1990 through 2020.Results: Of 65 patients with RGD (41 women, 24 men; median age at diagnosis, 62 years), 37 had IGD, 26 had PNGD, and 2 had IGDR. Fifty patients (76.9%) had an associated systemic condition; rheumatologic conditions were identified for 34 (52.3%) patients. The associated systemic condition occurred before RGD in approximately 75% of patients. Statistical analyses did not show significant associations between specific subtypes of RGD and systemic diseases or treatment response, and specific histopathologic findings were not predictive of an associated systemic disease.Conclusions: Although most patients with RGD had an associated systemic condition, subtypes of RGD did not correlate with systemic associations, lending support to the use of the umbrella term RGD.
- 1 April 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (4) , 989-1005
Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
- 1 April 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (4) , 989-1005
Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms
- 3 October 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 72-76
Use of spironolactone to treat acne in adolescent females
Background/objectives: Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we sought to examine spironolactone's role in treating this patient population.Methods: A retrospective review was performed to determine the efficacy of spironolactone treatment in adolescent females seen at Mayo Clinic in Rochester, Minnesota, from 2007 to 2017.Results: In a cohort of 80 pediatric patients with a median age of 19 years (range, 14‐20 years), 64 patients (80%) experienced improvement of acne on treatment with spironolactone (median dose, 100 mg daily) with a favorable side effect profile. Approximately a quarter of patients (22.5%) had a complete response; more than half (58.8%) had a complete response or a partial response greater than 50%. Initial and maximal responses were observed at a median of 3 months and 5 months, respectively. Patients received treatment with spironolactone for a median duration of 7 months (range, 3‐45 months) with limited side effects.Conclusions: Spironolactone demonstrated efficacy in treating acne in adolescent females and is a safe long‐term alternative to systemic antibiotics in these patients.
- 3 October 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 72-76
Use of spironolactone to treat acne in adolescent females
Background/objectives: Studies assessing the utility of spironolactone for treating acne in adolescent females are lacking. Thus, we sought to examine spironolactone's role in treating this patient population.Methods: A retrospective review was performed to determine the efficacy of spironolactone treatment in adolescent females seen at Mayo Clinic in Rochester, Minnesota, from 2007 to 2017.Results: In a cohort of 80 pediatric patients with a median age of 19 years (range, 14‐20 years), 64 patients (80%) experienced improvement of acne on treatment with spironolactone (median dose, 100 mg daily) with a favorable side effect profile. Approximately a quarter of patients (22.5%) had a complete response; more than half (58.8%) had a complete response or a partial response greater than 50%. Initial and maximal responses were observed at a median of 3 months and 5 months, respectively. Patients received treatment with spironolactone for a median duration of 7 months (range, 3‐45 months) with limited side effects.Conclusions: Spironolactone demonstrated efficacy in treating acne in adolescent females and is a safe long‐term alternative to systemic antibiotics in these patients.
- 30 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (4) , 611
Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains)
Click on the article title to read more.
- 30 September 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (4) , 611
Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains)
Click on the article title to read more.
- 20 February 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9) , 2106-2110
Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017
Background: Few large studies have assessed spironolactone treatment of adult female acne.Objectives: To explore the role of spironolactone in the treatment of adult female acne.Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.Conclusions: Spironolactone is a safe and effective treatment of acne for women.
- 20 February 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9) , 2106-2110
Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017
Background: Few large studies have assessed spironolactone treatment of adult female acne.Objectives: To explore the role of spironolactone in the treatment of adult female acne.Methods: We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.Results: In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.Conclusions: Spironolactone is a safe and effective treatment of acne for women.
- 1 January 2020
- Published by Elsevier in Clinics in Dermatology
- Vol. 38 (1) , 126-128
Personal reflections on mentorship as a pathway toward sustaining a joyful dermatologic practice: Part I: Influential mentors during training and early career
- 1 January 2020
- Published by Elsevier in Clinics in Dermatology
- Vol. 38 (1) , 126-128
Personal reflections on mentorship as a pathway toward sustaining a joyful dermatologic practice: Part I: Influential mentors during training and early career
- 1 September 2019
- Published by Elsevier in Clinics in Dermatology
- Vol. 37 (5) , 604-606
Personal reflections on mentorship as a pathway toward sustaining a joyful dermatologic practice: Part II: Our colleagues, our students, and our patients
- 1 September 2019
- Published by Elsevier in Clinics in Dermatology
- Vol. 37 (5) , 604-606
Personal reflections on mentorship as a pathway toward sustaining a joyful dermatologic practice: Part II: Our colleagues, our students, and our patients
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1658-1663
Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1658-1663
Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013
- 25 September 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 44 (5) , e189-e192
Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.
- 25 September 2018
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 44 (5) , e189-e192
Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012–2017
In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017. Of 28 patients identified (mean age 57.0 years; 96% female), 19 (68%) had clinical improvement of their CC with TST, 7 (25%) had no response and 2 (7%) had unknown response. There were adverse events in three patients: two had skin irritation and the third, who had a zinc allergy, experienced pain with application. Overall, our findings support those of previous case reports that TST appears to be a relatively well‐tolerated adjuvant treatment for CC, although future studies with a control group are warranted to assess the true efficacy of TST for the indication of CC.